Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics develops cancer drugs that target specific genetic mutations in tumors. It last closed at $0.45 on Nov 17, up 11.14% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From APRE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on APRE in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.45.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 14 | Ladenburg Thalmann | Initiated | Buy | $2 |
| Aug 13 | Wedbush | Maintained | Buy | $3 |
| May 7 | Oppenheimer | Initiated | Buy | $5 |
Technical Analysis
The stock is 7% below its 20 day and 35% below its 50 day average. It is 62% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot at $0.43, and the nearest resistance the Pivot R1 at $0.48.
| RSI (14) | 40.33 | Middle of its range | Neutral |
| MACD | -0.05 | Below its signal line | Bearish |
| Stochastic | 17.4 | Near the bottom of its range | Oversold |
| ADX (14) | 30.7 | Trending down | |
| Williams %R | -57.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -116.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −12.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.05 | Typical daily range, 11.6% of price |
| RSI (14) | 34.95 | Weak, oversold below 30 | Neutral |
| MACD | -0.10 | Below its signal line | Bearish |
| Stochastic | 7.6 | Near the bottom of its range | Oversold |
| ADX (14) | 15.9 | No clear trend | |
| Williams %R | -91.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -146.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −41.5% | Change over 10 sessions | Bearish |
| ATR (14) | $0.14 | Typical daily range, 30.4% of price |
What happened before
See how APRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How APRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in APRE in the last 90 days.
APRE Institutional Ownership
Full report →- ▲13 buying vs 11 selling
- ▲Held by funds +5.5 pts
- ▲Funds holding +1
- ▼Superinvestors: 0 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 29 | 28 | +3.6% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 23.6% | 18.2% | +5.5 pts |
| New / increased | 6 / 7 | 8 / 6 | −7.1% |
| Reduced / sold out | 5 / 6 | 5 / 2 | +57.1% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether APRE is in one of them and how their past APRE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered APRE in an article yet. Here's the latest on the wider market.
About Aprea Therapeutics
Aprea Therapeutics is a pharmaceutical company based in Doylestown, Pennsylvania, that develops cancer drugs. It focuses on treatments designed to target specific genetic mutations found in certain tumors. Its lead candidates are small molecule drugs, APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor, which are in clinical trials. The company aims these treatments at patients whose cancers carry particular mutations, and its drugs are still in development.
- Headquarters
- Doylestown, PA

